CN105593378B - 用于在人ezh2基因中检测突变的方法和组合物 - Google Patents

用于在人ezh2基因中检测突变的方法和组合物 Download PDF

Info

Publication number
CN105593378B
CN105593378B CN201480055312.0A CN201480055312A CN105593378B CN 105593378 B CN105593378 B CN 105593378B CN 201480055312 A CN201480055312 A CN 201480055312A CN 105593378 B CN105593378 B CN 105593378B
Authority
CN
China
Prior art keywords
artificial sequence
dna
comment
source
description
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480055312.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105593378A (zh
Inventor
X.M.马
C.马诺哈尔
A.詹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN105593378A publication Critical patent/CN105593378A/zh
Application granted granted Critical
Publication of CN105593378B publication Critical patent/CN105593378B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480055312.0A 2013-10-09 2014-10-07 用于在人ezh2基因中检测突变的方法和组合物 Active CN105593378B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888660P 2013-10-09 2013-10-09
US61/888660 2013-10-09
PCT/EP2014/071372 WO2015052147A1 (en) 2013-10-09 2014-10-07 Methods and compositions for detecting mutation in the human ezh2 gene

Publications (2)

Publication Number Publication Date
CN105593378A CN105593378A (zh) 2016-05-18
CN105593378B true CN105593378B (zh) 2019-09-20

Family

ID=51663175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480055312.0A Active CN105593378B (zh) 2013-10-09 2014-10-07 用于在人ezh2基因中检测突变的方法和组合物

Country Status (7)

Country Link
US (1) US10260102B2 (enExample)
EP (1) EP3055422B1 (enExample)
JP (1) JP6619332B2 (enExample)
CN (1) CN105593378B (enExample)
CA (1) CA2923706C (enExample)
ES (1) ES2705573T3 (enExample)
WO (1) WO2015052147A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6619332B2 (ja) 2013-10-09 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトｅｚｈ２遺伝子中の変異を検出するための方法及び組成物
PL3157527T3 (pl) 2014-06-17 2023-08-07 Epizyme, Inc. Inhibitory ezh2 do leczenia chłoniaka
US20180133211A1 (en) * 2015-05-19 2018-05-17 Mayo Foundation For Medical Education And Research Methods and materials for promoting bone formation
US20180321256A1 (en) 2015-11-05 2018-11-08 Epizyme, Inc. Flow cytometry for monitoring histone h3 methylation status
EP3407978A4 (en) * 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
CN112226513B (zh) * 2020-10-29 2022-02-01 华中科技大学 一种检测ezh2基因可变剪切位点突变的引物、试剂盒及应用
CN120624641A (zh) * 2025-02-20 2025-09-12 宁波熙宁检测技术有限公司 一种用于检测ezh2基因突变的核酸组合物、试剂盒及检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049770A3 (en) * 2011-09-30 2014-05-15 Glaxosmithkline Llc Methods of treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981176A (en) 1992-06-17 1999-11-09 City Of Hope Method of detecting and discriminating between nucleic acid sequences
EP0866071B1 (en) 1997-03-20 2004-10-20 F. Hoffmann-La Roche Ag Modified primers
EP1241266A4 (en) 1999-12-10 2004-11-17 Toyo Boseki METHOD FOR DETECTING NUCLEIC ACID POLYMORPHISMS
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
JP2009247231A (ja) * 2008-04-02 2009-10-29 Olympus Corp 標的塩基判別方法
EP2337865B1 (en) 2008-10-20 2014-11-19 Roche Diagnostics GmbH Allele-specific amplification using a primer with a modified nucleotide
US20100143901A1 (en) 2008-12-09 2010-06-10 Roche Molecular Systems, Inc. Nuclease-Free Real-Time Detection of Nucleic Acids
CN101993934A (zh) 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种ezh2基因的原位杂交检测试剂盒及其检测方法和应用
WO2013086639A1 (en) * 2011-12-14 2013-06-20 British Columbia Cancer Agency Branch Mutations indicative of weaver syndrome
JP6619332B2 (ja) 2013-10-09 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトｅｚｈ２遺伝子中の変異を検出するための方法及び組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049770A3 (en) * 2011-09-30 2014-05-15 Glaxosmithkline Llc Methods of treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EZH2 and CD79B Mutational Status Over Time in B-Cell Non-Hodgkin Lymphomas Detected by High-Throughput Sequencing Using Minimal Samples;Saieg MA et al.;《Cancer Cytopathology》;20130731;第121卷(第7期);第379页右栏第1段和第3段，第382页左栏第2段第12-15行以及右栏第2段第9-12行 *
EZH2 mutations are frequent and represent an early event in follicular lymphoma;Boedoer Csaba et al.;《Blood》;20130930;第122卷(第18期);表1 *
双错配碱基ARMS结合RE法快速检测FGFR3基因的突变超热点;郭奕斌等;《分子诊断与治疗杂志》;20100131;第2卷(第1期);第6页右栏第3段及第8页左栏第2段 *

Also Published As

Publication number Publication date
CN105593378A (zh) 2016-05-18
CA2923706A1 (en) 2015-04-16
JP2016533708A (ja) 2016-11-04
WO2015052147A1 (en) 2015-04-16
CA2923706C (en) 2020-08-25
ES2705573T3 (es) 2019-03-26
EP3055422B1 (en) 2018-11-14
JP6619332B2 (ja) 2019-12-11
US10260102B2 (en) 2019-04-16
US20150099747A1 (en) 2015-04-09
EP3055422A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
CN105593378B (zh) 用于在人ezh2基因中检测突变的方法和组合物
US8455190B2 (en) Enrichment of a target sequence
US20120164641A1 (en) Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
CN110438223B (zh) 检测Kras基因点突变的引物、探针及其试剂盒与检测方法
US20140287404A1 (en) Detection of bisulfite converted nucleotide sequences
CN108026583A (zh) Hla-b*15:02的单核苷酸多态性及其应用
EP2971075B1 (en) Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
EP4074840A1 (en) Pcr method and pcr kit for increasing allelic discrimination
CN105473736A (zh) 基于纳米探针的遗传学检验
JP5602355B2 (ja) 癌患者の外科的手術後の治療選択方法及び予後診断
JP6153758B2 (ja) 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット
JP6205216B2 (ja) 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
JPWO2013157625A1 (ja) Ｈｌａ−ａ＊２４：０２を検出する方法、及び検出キット
JP5635496B2 (ja) Ｅｇｆｒ遺伝子多型検出用プローブおよびその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant